Day: September 26, 2024

PRINCETON, N.J., Sept. 26, 2024 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched Ketoconazole Shampoo, 2%. ANI’s Ketoconazole Shampoo, 2% is the generic version of the reference listed drug (RLD) Nizoral®. “We are proud to announce the FDA approval and commercialization of Ketoconazole Shampoo, 2%, another limited competition product. ANI’s talented R&D team continues to execute on our key strategic priority to consistently and effectively launch new products that address the needs of patients,” stated Nikhil Lalwani, President and Chief Executive Officer of ANI. U.S. annual sales for Ketoconazole Shampoo, 2% total approximately...

ATLANTA and WATERLOO, Ontario, Sept. 26, 2024 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, will showcase supply chain and logistics technology innovations for transportation management; routing, mobile and telematics; and freight forwarders, customs brokers and air cargo at its 2024 Innovation Forum event, which takes place October 8-10, 2024 at the Hyatt Regency O’Hare Chicago.   “In a time with many logistical challenges and opportunities, Descartes is focused on bringing leading software solutions and capabilities to market to help our global customer base drive higher levels of supply chain efficiency, security, resilience and competitive advantage,” said Ken Wood, Executive Vice President, Product Management at Descartes....

Reference is made to the notice on 25 September 2024 regarding issue of Tranche 1 shares of the private placement completed on 16 September 2024. The private placement consisted of two tranches, with total gross proceeds amounting to NOK 70 million. The share capital increase related to the Tranche 1 shares has been registered and the shares will be delivered soonest. The Tranche 1 shares will be delivered on a separate and non-tradable ISIN, pending publication by the Company of a prospectus approved by the Norwegian Financial Supervisory Authority. Following the issue, the Company’s share capital will be NOK 66,056,228.10 divided into 440,374,854 shares, each with a nominal value of NOK 0.15. For further information contact:Marianne Bøe, Investor RelationsE-mail: marianne.boe@idexbiometrics.comTel: +47 918 00186 About IDEX BiometricsIDEX...

Achieved first lithium production, advancing Volt Lithium’s commitment to securing a North American supply of lithium Commence cash generation by the end of 2024 with the goal to be cash flow positive in the first half of 2025 Poised for long-term cost-effective growth underpinned by one of the lowest DLE operating cost structures in North AmericaCALGARY, Alberta, Sept. 26, 2024 (GLOBE NEWSWIRE) — Volt Lithium Corp. (TSXV: VLT | OTCQB: VLTLF I FSE: I2D) (“Volt” or the “Company“) announces that the Company has commenced U.S. field operations in the Permian Basin in Texas, achieving the significant milestone of first lithium production. “Achieving first lithium production establishes Volt as a leader in direct lithium extraction from North American oilfield brines and marks the Company’s strategic shift...

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE MICROTUBULE PROGRAM AB8939 AND IN PARTICULAR THE ABILITY OF AB8939 TO GENERATE RESPONSE ON MECOM REARRANGEMENT Paris, 26 September 2024, 8.30am CET AB Science SA (Euronext – FR0010557264 – AB) today provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement. AB8939 is a novel microtubule destabilizer currently evaluated in phase 1 clinical trial (study AB18001, NCT05211570) in patients with refractory and relapsed acute myeloid leukemia (AML). The phase 1 clinical trial of AB8939 completed its first step, consisting in determining the maximum tolerated dose following 3 consecutive days of AB8939 treatment, and was authorized to proceed with the next step, consisting in determining the maximum tolerated...

Paris, 26th of September 2024 — Virtune, a Swedish regulated digital asset manager and issuer of crypto Exchange Traded Products (ETPs) based in Stockholm, Sweden, announces its expansion into France through the listing of its Virtune Staked Solana ETP on Euronext Paris. With strong traction and consistent inflows in the Nordic regions driven by increasing interest and crypto adoption, expanding into France is a strategic milestone for Virtune. Virtune has since its inception in May 2023 been growing rapidly in the Nordics where it has listed a total of 12 products and reached more than 31 000 investors in its products in just about one year. The key success factors have been an educational focus, a transparent market approach and through its regulated status. This move not only addresses growing investor enthusiasm but also enhances our...